A5039471367- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Ion channel regulation and function
- Signaling Pathways in Disease
- Synthesis and Biological Evaluation
- Error Correcting Code Techniques
- Sarcoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Galectins and Cancer Biology
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Radiopharmaceutical Chemistry and Applications
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- MicroRNA in disease regulation
- T-cell and Retrovirus Studies
Zhengzhou University
2016-2025
Henan Cancer Hospital
2015-2025
Wuhan University
2023
Second Affiliated Hospital of Zhengzhou University
2017
Hunan University
2015
First Affiliated Hospital of Zhengzhou University
2009-2010
The aim of this study was to correlate matrix metalloproteinase-2 and metalloproteinase-9 expression with the clinicopathological features outcome patients early gastric cancer clinically elucidate more information on role protein overexpression regard lymph node metastasis cancer. levels were assessed by immunohistochemistry. An association observed between metalloproteinase-2, metalloproteinase-9, metalloproteinase-2/matrix factors, such as ulceration metastasis. Furthermore, both strongly...
Purpose: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was retrospectively evaluate the safety and clinical efficacy chemotherapy combined with anlotinib plus maintenance in advanced/metastatic soft tissue sarcoma (STS) patients real-world setting China. Patients Methods: We collected medical data thirty-two STS who received therapy. objective response rate...
Abstract Anthracycline-based chemotherapy resistance represents a major challenge in diffuse large B-cell lymphoma (DLBCL). MiRNA and gene expression profiles ( n = 47) were determined to uncover potential chemoresistance mechanisms therapeutic approaches. An independent correlation between high of miRNA-363-3p was observed validated larger cohort 106). MiRNA-363-3p shown reduce doxorubicin-induced apoptosis tumor shrinkage vitro vivo experiments by ectopic CRISPR/Cas9-mediated knockout...
More effective regimens for advanced esophageal squamous cell carcinoma (ESCC) are urgently needed. Therefore, a retrospective study concerning the efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) versus solvent-based (sb-TP) as first-line therapy was conducted in Chinese patients with ESCC.From June 2009 to 2015, 32 were treated nab-paclitaxel (125 mg/m2) on first eighth days (30 minutes infusion) (75 second day every 21 (nab-TP arm). Also, 43 (80...
The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in asparaginase-resistant NKTCL; however, only a portion benefit and the median response duration rather short. Treatment strategies have not been identified for immunotherapy-resistant NKTCL. We describe patient primary cutaneous NKTCL experienced disease progression after pegaspargase-based chemotherapy PD-1 inhibitor (sintilimab)-based...
There is currently no standard first-line regimen for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTCL). In this study, we investigated the efficacy and toxicity of gemcitabine (GEM) combined oxaliplatin (L-OHP), L-asparaginase (L-ASP) dexamethasone (DXM) (GOLD regimen) as a systemic treatment scheme newly-diagnosed ENKTCL cases. A total 55 were recruited at Henan Province Cancer Hospital Center Sun Yat-sen University between May, 2008 August, 2012. The GOLD included...
The present study aimed to investigate microRNA-376a (miR-376a) expression in lymphoma, and the effect of miR-376a on cell proliferation apoptosis at cytological molecular levels. lymphoma issue cells was detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR), forkhead box protein P2 (FOXP2) RT-qPCR western blot analysis, were studied an MTT assay flow cytometry, respectively. Additionally, levels cyclin D2, A, B, apoptosis-associated proteins B-cell 2 (Bcl-2)...
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) P53 tumor suppressors are among the most commonly inactivated or mutated genes in human cancers, whose pathways cross-talk interact a complementary mode. In order to understand their roles relationship diffuse large B-cell lymphoma (DLBCL), we examined expression evaluated prognostic significance 62 patients with DLBCL treated standard chemotherapy. Results showed that PTEN protein was lost 23 (37.1%) cases, loss associated...
Abstract Objective: Extranodal involvement represents a peculiar presentation of diffuse large B-cell lymphoma (DLBCL). Previous studies have suggested that older patients are more prone to extranodal involvement. This study retrospectively addressed the distribution, prognostic value and treatment options in young with DLBCL. Methods: A total 329 were enrolled according inclusion requirements. The effects gender, involvement, age-adjusted international index (aaIPI), rituximab infusion...
Abstract Background Early progression after the first-line R-CHOP treatment leads to a very dismal outcome and necessitates alternative for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed develop genetic predictive model early evaluate its potential in advancing treatment. Methods Thirty-two hotspot driver genes were examined 145 DLBCL 5 cell lines using next-generation sequencing. The association of clinical features, cell-of-origin, double expression, positive p53...
Aim: Advanced esophageal squamous cell carcinoma (ESCC) is a lethal disease with poor response to conventional chemotherapy. Immunotherapy showed better activity than chemotherapy in late-line treatment. However, the rate and duration of are far from satisfactory. The efficacy an anti-angiogenic agent combined immunotherapy for ESCC unknown. Results: A patient experienced relapse after chemo-radiotherapy. progressed combination regimen PD-1 inhibitor camrelizumab apatinib was administered....
PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When failed, alternative options are limited. In the past few years, we have used anti-angiogenic agent apatinib and PD-1 camrelizumab treat cHL patients who failed prior immunotherapy. this study, analyzed data...
Summary With the rapid development of smartphones in recent years, we have witnessed an exponential growth number mobile apps. Considering security and management issues, network operators need to a clear visibility into apps running network. To this end, paper presents novel approach generating fingerprints for from traffic. The that characterize unique behaviors specific can be used identify real In order handle large volume traffic efficiently, use non‐negative matrix factorization (NMF)...
The purpose of this retrospective study was to evaluate the safety and efficacy docetaxel, oxaliplatin plus fluorouracil (DOF) regimen in comparison with epirubicin, cisplatin (ECF) treating AGC. A total 88 AGC patients were treated DOF (N = 45) ECF 43) respectively. end points response rate, survival, toxicity. overall rates for 42·2% 37·3%, respective tumour control 80% 60·6%, While median progression-free survival (PFS) approached 6·7 5·0 months ECF, (OS) 11·4 9·8 Although both groups...
Abstract: Early T-cell precursor (ETP) leukemia represents a new subtype of T-lymphoblastic leukemia/lymphoma with unique immunophenotypes expressing and one or more the myeloid/stem cell markers. Here, we report young patient who had primary mediastinal mass pleural effusion without bone marrow involvement. A CT-guided biopsy flow cytometry analysis revealed blast cells to have complicated immunophenotypes: strongly expressed antigen CD7, myeloid-lineage antigens CD33 CD13 stem markers...
Primary testicular lymphoma (PTL) is a rare malignancy of testis. Although the multimodality treatment (including orchiectomy, systemic chemotherapy, scrotal radiotherapy, and preventive central nervous system (CNS)-targeted treatment) widely used to treat PTL, recurrence, especially CNS occurred frequently. Patients with relapsed PTL have dismal prognosis limited options. In this report, we described case 63-year-old man early-stage PTL. The patient received treatment, but relapse 3 months...
Aim: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure is a rigorous problem patients diffuse large B-cell lymphoma (DLBCL), which usually predicts poor survival. The study explored the association of microRNAs R-CHOP resistance order to find reliable predictive factors novel therapeutic targets. Methods: Forty-five newly diagnosed cases DLBCL were administered regimen. Thirty-three them divided into sensitive group 12...
// Hai-ying Wang 1 , Zhi-hua Yao Hong Tang Yan Zhao Shui-ling Jin 2 Wen-ping Zhou Shu-na Shu-jun Yang Yan-yan Liu Su-xia Luo Department of Medical Oncology Henan Cancer Hospital, Zhengzhou University Affiliated Zhengzhou, Henan, China Internal Medicine, The Second Hospital University, Correspondence to: Luo, email: 470242877@qq.com Wang, luosxrm@163.com Keywords: advanced esophageal squamous cell carcinoma, Paclitaxel, S-1, cisplatin, palliative chemotherap Received: July 18,...